A drug that has been obtained from Cannabis extracts helps in the reduction of pain associated with rheumatoid arthritis. However, those who believed that the patient now smoke joints, is wrong.
The medicine (Sativex) was developed by the British company GW Pharmaceuticals, which has a license from the government to research the benefits of cannabis. Tests with a spray version of the preparation at 58 arthritis patients showed that it reduces pain and improves sleep quality. Few patients developed side effects.
Philip Robson, director of the research department: "These results are really exciting because this is the first controlled clinical trial of a cannabis-based drug is for the treatment of arthritis”. The study is now focused on the optimal treatment dose.
The Arthritis Research Campaign has welcomed the study. A spokeswoman said: "It will not cure the disease, but it will do a lot to manage pain and suffering of people with rheumatoid arthritis." Furthermore , cannabis is less likely to be harmful than other painkillers. The idea that people with rheumatoid arthritis smoking joints and getting high, is wrong. Painkillers that are based on cannabis, should be taken seriously.
Previously, scientists commissioned by the Arthritis Research Campaign conducted studies which showed that cannabidiol, a natural component of cannabis, which in its processed form has no psyche-changing effect, can ease the effects of collagen-induced arthritis in mice.
WANC 18:06:04 / pte
Study: Cannabidiol (CBD) may help treat social anxiety disorder
The relationship between cannabis and anxiety is very interesting. Large detetrahidrocannabinol concentrations (THC) is often associated episodes of paranoia and anxiety, but is well documented that cannabidiol (CBD) in cannabis may counteract this effect.
, an article published in the Journal of Psychopharmacology 2011 by a group of Brazilian researchers examined the relationship between cannabidiol (CBD) and social anxiety disorder (SAD). Their results suggest that CBD could be a way for people who suffer from SAD to help, offer to manage your symptoms.
What is Social Anxiety Disorder (SAD)?
What is the impact on 12% of Americans in his life, social anxiety disorder (SAD) is the most common form of anxiety and one of the psychiatric disorders in general. It is also called social phobia.
By definition of social anxiety disorder is characterized by an intense fear in one or more social situations. In turn, this fear may distress to the point, cause impaired daily functioning.
Brazilian researchers are investigating CBD, fear in the people. To understand the relationship between cannabidiol (CBD) and anxiety test, the research team from Brazil recruited 10 individuals with a diagnosis of social anxiety disorder (SAD). We then functional imaging to measure the amount of blood flow to various parts of the brain, having regard to the effects of CBD.
At the first meeting half an oral dose of 400 mg cannabidiol (CBD) and the other half were treated with placebos received. in the second session these roles were reversed, so that all 10 particpants were treated with CBD at any given time. "These results suggest that CBD reduces anxiety in SAD and that this paralimbic related to its effects on activity in limbic areas in the brain” - Dr. JA Crippa
According to the results of the study was associated opinion cannabidiol (CBD) with a significant decrease in anxiety. Cerebral blood flow after treatment CBD also seems to an anxiolytic (anti-anxiety) in areas of the brain, the emotions refer to control. Extension, what does all this mean, Dr. JA Crippa, head of the research team in Brazil. "These results suggest that CBD reduces anxiety in SAD and that this on its effects on activity in limbic brain areas and related paralimbic" says Crippa.
Science / cells: basic research shows that non-psychotropic cannabinoids cannabidiol are effective as anti-cancer drugs in leukemia
New research has shown that no psychotropic cannabinoids of the cannabis plant could be effective anti-cancer drugs. The anti-cancer properties of THC, the primary psychoactive component of cannabis, are recognized for many years. The study was conducted by the team at the St. George's University in London with leukemia cells. The team of Dr. Wai Liu and his colleagues conducted laboratory tests with a number of cannabinoids, either alone or in combination with the other. Of the studied cannabinoids exhibited any such strong anti-cancer properties as THC. Remarkably, they showed when combined together an increased effect on the cancer cells,.
Dr. Liu said: "These substances are able to affect the development of cancer cells to stop them on their way and prevent them from growing. they can destroy cancer cells In some cases, through the use of specific dosage pattern. In combination with available treatment methods we could discover some highly effective strategies for cancer therapy. "The study examined cannabidiol (CBD), cannabigerol (CBG) and Cannabigevarin (CBGV).
Press release of the St George's University of London. October 14, 2013
Cannabis Research: Alzheimer’s Disease
Alzheimer’s is a physical disease of the brain and one of the most common causes of dementia. It causes the formation of “extracellular” and “fibrillar” deposits, which means that cells die in the brain. This progressive disorder causes slowly more and more brain damage, in which the mental condition of the patient gradually deteriorated. The symptoms of Alzheimer’s disease are:
Memory Loss – Is easily confused and finds it difficult to remember names, places, people and recent events.
Mood swings – Can easily be angry, anxious or frustrated as a result of increasing memory loss.
Withdrawal – Pulls emotionally still further back, the more difficult the communication.
Cannabis & Alzheimer’s studies:
1) prevention of Alzheimer’s disease pathology by cannabinoids: neuroprotection by blockade of microglial activation (Prevention of Alzheimer’s Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation – 2005)
Cannabinoids are known to act as neuroprotective agents in the brain. This prompted the researchers, the function of the cannabinoid receptors and the possible protective properties that have the cannabinoids in marijuana to judge in Alzheimer’s patients. They found that the cannabinoid receptors play a role in the illness and that prevent the cannabinoids that the neurodegenerative process is taking place. Published in the “Journal of Neuroscience.”
2) Marijuana slows decay by Alzheimer’s disease (Marijuana Slows Alzheimer’s Decline – 2005)
Studies of the Hebrew University in Jerusalem, who were eye aimed to find out whether the non-psychedelic cannabinoids in cannabis may help in the treatment of Alzheimer’s disease. They found positive results in mice, which indicated that the use of cannabis could slow down the degeneration of memory. Published by the “Israel National News”.
3) A molecular link between the active component of marijuana and Alzheimer’s disease pathology (A Molecular Link Between The Active Component of Marijuana and Alzheimer’s Disease Pathology – 2006)
This research aimed to find out what role THC, in contrast to the non-psychoactive cannabinoids, could play in the treatment of Alzheimer’s disease. It has been found that THC inhibits effectively the AB Group, the principal pathological markers of Alzheimer’s disease. They took together that the effect that had THC, was even better than that of prescription drugs that were at the time available. Published in “Molecular Pharmaceuticals.”
Cancer is a large group of diseases, which results in uncontrolled and rapid cell growth. Due to the uncontrolled growth of the cancer cells invade the surrounding healthy tissue and destroy it. Cancer usually starts in one part of the body, but can spread through the bloodstream and lymphatic system. There are more than 200 types of cancer that occur in humans, which all have different symptoms, depending on where they are located.
Brain cancer studies:
1) Anti-tumor effects of cannabidiol, a non-psychoactive cannabinoid, on human glioma cell lines (anti-tumor effects of cannabidiol, a cannabinoid Nonpsychoactive, on Human Glioma Cell Lines - 2003)
Under laboratory conditions, research has been conducted in order to investigate the hypothesis that CBD have anti-tumor properties. It was found that CBD is the viability of the tumor cells dropped significantly, suggesting that CBD is an effective antitumor agent. Published in the "Journal of Pharmacology and Experimental Therapeutics."
2) Neuroprotection by Δ9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain induced by excitotoxicity in the living organism (Neuroprotection by Δ9-Tetrahydrocannabinol, the Main Active Compound in Marijuana, against Ouabain-Induced In Vivo excitotoxicity - 2001)
This research was designed to investigate the effects of THC on acute brain damage and brain degenerative diseases. It has been found that THC has an effect that protects the brain from degenerative diseases. Published in the "Journal of Neuroscience."
3) A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme (A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme - 2006)
This study was the first that was designed to explore the antitumor properties of cannabinoids in a clinical setting. She came to positive results, and it was found that THC and other cannabinoids inhibit tumor growth in patients. Published in the "British Journal of Cancer."
4) A combined preclinical therapy of cannabinoids and temozolomide against glioma (A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma - 2011)
This research aimed to evaluate the use of THC in conjunction with the drug TMZ in the treatment of glioblastoma multiforme - the most common and very resistant form of brain cancer. It has been found that the combined treatment showed that the reversed-tumor activity. Published in the journal "Molecular Cancer Therapeutics."
Breast cancer studies:
1) Anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma (anti-tumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma - 2006)
This research recognizes the antitumor effects of THC, but claims that it was problematic because of its psychoactive properties. Therefore, they went on to assess the effects of other cannabinoids. It was found that CBD showed promising anticarcinogenic characteristics that should be investigated further. Published in the "Journal of Pharmacology and Experimental Therapeutics."
2) pathways in mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion and metastasis (Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis - 2010)
This study was designed to determine the effects of CBD on breast cancer cells. It was found that it inhibited the growth and the spread of these cancer cells. It has also been discovered that CBD significantly reduced the tumor mass. Published in the "U.S. Library of Medicine."
3) Cannabinoids reduce ErbB2-driven breast cancer progression through AKT inhibition (Cannabinoids reduce ErbB2-driven breast cancer progression through AKT inhibition - 2010)
This research describes experiments that were performed to assess the effects of cannabinoids on the very aggressive ERB2-positive breast cancer. They concluded that cannabinoids both tumor growth, as well as the amount of existing tumors appeared to decrease, which strongly suggests that they represent a real application for the therapeutic treatment of breast cancer. Published in the journal "Molecular Cancer."
4) The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation (The endogenous cannabinoid anandamide Inhibits human breast cancer cell proliferation - 1998)
This research was designed to investigate the effects of cannabinoids on the proliferation of breast cancer cells. It has been found to inhibit the growth. Published in the "National Academy of Sciences (PNAS)."
Lung cancer studies:
1) Δ9-Tetrahydrocannabinol inhibits both triggered by the epithelial growth factor lung cancer cell migration outside of the living organism, as well as the growth and metastasis in the living organism (Δ9-Tetrahydrocannabinol Inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo - 2008)
This research was conducted to study the effects of THC to the epithelial growth factor induced by cancer - a particularly aggressive and resistant to chemotherapy form of cancer. It was found that THC has played a significant role in inhibiting cancer growth, which justifies further research in this direction. Published in the journal "Oncogene."
2) Cannabidiol inhibits lung cancer cell invasion and metastasis via the intercellular adhesion molecule-1 (Cannabidiol Inhibits lung cancer cell invasion and metastasis via intercellular adhesion molecule-1-2011)
In this research, it was tried to examine the effects of CBD on the invasiveness of cancer. It has been found that cannabinoids inhibit the invasiveness of the primary tumor cells in patients with lung cancer. Published in the "U.S. National Library of Medicine."
3) The cannabinoid receptors CB1 and CB2 as new targets for the inhibition of large cell lung cancer growth and metastasis (cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis - 2011)
This research was conducted to determine the role of the cannabinoid receptor activation in lung cancer. It has been found that both inhibit the growth of cancer cells and enhance their apoptosis - the natural process of cell death. Published in the "U.S. National Library of Medicine."
Prostate cancer studies:
1) Anti-proliferative and apoptotic effects of anandamide in human Prostatakrebszellinien: implication of the reduction of epidermal growth factor receptors and ceramide production (anti-proliferative and apoptotic effects of anandamide in human prostatic cancer cell lines: implication of epidermal growth factor receptor down-regulation and ceramide production - 2003)
This study describes how the activation of cannabinoid receptors causes an antiproliferative effect in cancer cells in the prostate, which has major implications for the treatment of prostate cancer. Published in the "U.S. National Library of Medicine."
2) The role of cannabinoids in prostate cancer: basic scientific point of view and possible clinical applications (The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications - 2012)
This study conducted a multi-evaluation of many other previous research on prostate cancer to determine whether cannabinoids have a practical clinical application. It has been found that it is in everyone's best interest to conduct clinical trials of medical cannabis. Published in the "U.S. National Library of Medicine."
3) Non-THC Cannabinoids inhibit prostate cancer growth in vitro and in vivo: Pro-apoptotic effects and the underlying mechanisms (non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms - 2013)
This research was designed to extend the previously explored idea that cannabinoid receptor activation causes cell death in prostate cancer cells. The research found significant positive results and found that the data supported the clinical tests of CBD from prostate cancer patients. Published in the "U.S. National Library of Medicine."
Blood cancer studies:
1) cannabinoid receptor-mediated apoptosis induced by R (+)-methanandamide and WIN55 0.212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma (Cannabinoid Receptor-Mediated Apoptosis Induced by R (+)-Methanandamide and WIN55, 212 - 2 Is Associated with Ceramide Accumulation and p38 Activation in Mantle Cell Lymphoma - 2006)
This research was designed to explore whether cannabinoids inhibit cancer cells in lymphomas. It describes that it has been found that cannabinoids inhibit the growth and induce cell death in mantle cell lymphoma (blood cancer). Published in the journal "Molecular Pharmacology."
2) triggered by Δ9-tetrahydrocannabinol apoptosis in Jurkat T-leukemia cells is regulated by the translocation of BAD mitochondria. (Δ9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria - 2006)
This research discusses how the use of cannabinoids in apoptosis (regulated and the natural death of cells) is to be evaluated. They yielded positive results, and it was found that cannabinoids actually cause the death of carcinogenic leukemia cells. Published in the "U.S. National Library of Medicine."
3) Activation of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation (expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: Growth inhibition by receptor activation - 2008)
This research aimed to determine the effects of the cannabinoid receptor activation on lymphomas. It has been found that the cannabinoid receptor activation, the multiplication and growth of lymphoma reduced, and causes the death of some cancer cells. Published in "International Journal of Cancer."
Oral cancer studies:
Cannabinoids inhibit cellular respiration of human oral cancer cells (Cannabinoids inhibit cellular respiration of human oral cancer cells - 2010)
This research was aimed to investigate the effects of cannabinoids on cell respiration in certain types of oral cancer. It has been found that cannabinoids inhibit cancer cell respiration and therefore have a toxic effect on them. This implies that cannabinoids may be used for the treatment of oral cancer. Published in the "U.S. National Library of Medicine."
Liver cancer studies:
Anti-tumor effect of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy (Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy - 2011)
This research aimed to determine what the effects of THC on cancer cells in the liver. It has been found that the growth of THC and the effectiveness of these cancer cells is reduced, which means that THC should be further examined as a therapeutic treatment. Published in the "U.S. National Library of Medicine."
Pancreatic cancer studies:
Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes (Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via Endoplasmic Reticulum Stress-Related Genes - 2006)
This study suggests that pancreatic tumor tissue seems to have a much higher number of cannabinoid receptors compared to normal pancreatic tissues. The study found that, when the cannabinoids are administered to cancer cells began to die by apoptosis, resulting in a reduction in the growth and spread of the tumor. Published in "The American Journal of Cancer."
Chronic pain is pain that persists for more than 6 months. They are often a symptom of an underlying disease, such as cancer and multiple sclerosis, but can also be caused by a simple injury or infection. Chronic pain can take many forms, be it mild or excruciating and has in those affected usually a slow emotional impact. Prescribed drugs can often be ineffective or have undesirable side effects, so the effect of cannabis has been explored as a pain reliever.
Studies in this area:
1) Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, clinical cross-over study (Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical Trial - 2008)
This study was conducted to determine how effectively acts cannabis in the treatment of chronic pain caused by nerve, caused by HIV. Here it was found that participants reported with the use of cannabis from a better pain relief than those who were given a placebo and that it was most effective when it was used in conjunction with other pain relieving therapies. Published in the journal "Neuropsychopharmacology."
2) Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia by in healthy volunteers (Dose-dependent Effects of Smoked Cannabis on Capsaicin-induced Pain and Hyperalgesia in Healthy Volunteers - 2007)
Researchers conducted this study to examine how smoking cannabis would affect the perception of pain in patients induced with capsaicin pain suffered (the compound in chili peppers that causes a burning sensation when it comes in contact with tissue). They found that those who smoked a mean dose reported a significant reduction in pain, while those who smoked a higher dose, reported a significant increase in the induced pain. Published in the journal "Anesthesiology."
3) cannabinoids for the treatment of chronic pain that is not caused by tumors, a systematic review of randomized trials. (Cannabinoids for treatment of chronic non-cancer pain, a systematic review of randomized trials - 2011)
This study aimed to demonstrate the limited options that are available for those who suffer from chronic pain. They introduced random studies that compared the cannabis with a placebo and their effect on pain. It has been found that the use, cannabis, compared to those with a placebo, reported a significant pain reduction. Moreover, it has been found that the use of triggered no serious side effects. In summary, it was found that cannabinoids appear to be an effective and safe way to treat pain. Published in the "U.S. National Library of Medicine."
Cannabis Research: Diabetes
Diabetes mellitus is a group of diseases that is most commonly associated with a lack of insulin production, causing the blood sugar level is regulated wrong. There are two main types of diabetes, type 1 diabetes and type 2 diabetes. Patients who suffer from Type 1 diabetes, can ever produce no own natural insulin and are dependent on medication to survive. Type 2 diabetes patients do not produce enough insulin to support their body. This is a less severe form and can often be controlled with a strict diet. Untreated diabetes can lead to kidney failure, blindness, amputations and death.
To this end, studies carried out:
1) Cannabinoids block tactile allodynia in diabetic mice without attenuation of its antinociceptive effect. (Cannabinoids blocks tactile allodynia in diabetic mice without attenuation of its antinociceptive effect - 2004)
Caused by diabetes nerve pain is one of the most common causes of chronic pain. However, diabetics are less sensitive to the effects of analgesic drugs such as morphine and other opiates. This leaves the sufferer few options. This study was designed to assess the efficacy of cannabinoids in treating this type of pain. Through testing on diabetic mice found that cannabinoids may have a positive effect on pain reduction. Published in the "U.S. National Library of Medicine."
2) Cannabidiol lowers incidence of diabetes in non-obese diabetic mice (cannabidiol Lowers incidence of diabetes in non-obese diabetic mice - 2006)
This study was aimed to find out whether the cannabinoid CBD has an effect on the rate of diabetes-prone mice occurs in type 1 diabetes. It has been found that the onset of diabetes from a baseline of 86% in an untreated group to 30% in a group of mice treated with CBD, decreased. Published in "IngentaConnect."
3) Neuroprotective and blood-retinal barrier protective effects of cannabidiol in experimental diabetes. (Neuroprotective and Blood-Retinal Barrier-Preserving Effects if cannabidiol in experimental Diabetes2006)
This study examines how the non-psychoactive cannabinoid CBD may be applied to reduce damage to the retina caused by diabetes. Here, it was found that CBD inflammation, neurotoxicity and blood-retina in diabetic animals reduced expiration, indicating that the drug may be used to prevent the diabetic retinopathy. Published in the "U.S. National Library of Medicine.
Cannabis Research: Epilepsy
Epilepsy is a neurological disorder that causes intense bursts of electrical energy within the brain. This causes a temporary but recurring disorder, how the brain works - which leads to an epileptic seizure. An epileptic seizure can, among many other symptoms, loss of consciousness, sensory disturbances and convulsions Run.
1) cannabidiol shows antiepileptiforme properties and counteracts Krämofen; in vitro and in vivo (cannabidiol displays Antipileptiform and antiseizure Properties In Vitro and In Vivo - 2010)
This research aimed to experimentally explore the wider effects of CBD on its anticonvulsant properties in animals and in isolated tissue. It was found that CBD and its effects on the CB1 receptors showed the potential to inhibit epileptiform activity in isolated tissue samples and to reduce the severity of seizures in living animals. Published in the "U.S. National Library of Medicine."
2) Cannabidivarin has an antispasmodic effect in mice and rats (Cannabidivarin is anticonvulsant in mouse and rats - 2012)
This research was aimed to test the effect of the cannabinoid CBDV for cramps, such as those caused by epilepsy. It has been found that the use of such a cannabinoid effectively prevented convulsions and appeared to have no adverse effects on normal functions. Published in the "British Journal of Pharmacology."
3) Marijuana, Endocannabinoids and epilepsy: potentials and challenges for an improved therapeutic intervention (Marijuana, endocannabinoids, and epilepsy: potential and challenges for improved therapeutic intervention - 2013)
This research is a meta-study, which describes that the results of many other studies show apparently that cannabinoids and marijuana potentially beneficial for those act who suffer from neurological disorders such as epilepsy. Published in the "U.S. National Library of Medicine."
Cannabis Research: gastrointestinal disorders
A gastrointestinal disorder is a disorder in which the bowel appears normal, but is not functioning properly. Common examples of such a disorder are irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and constipation.
Studies in this area:
1) Cannabinoids and the gastrointestinal tract (gastrointestinal tract and the Cannabinoids - 2001)
This study aimed to evaluate the effect of cannabinoids on the digestive system. It was found that the activation of CB1 receptors in the endocannabinoid system inhibits the production of stomach acid, suggesting that it could be used by patients for whom too much is produced and who have irritable bowel symptoms. It has also been found that there appears to be no adverse effects or withdrawal symptoms were, which can be associated with the use of cannabinoids. Published in the journal "Good."
2) Differential expression of cannabinoid receptors in the human colon: Cannabinoids promote epithelial wound healing (Differential Expression of Cannabinoid Receptors in the Human Colon: Cannabinoids Promote Epithelial Wound Healing - 2005)
In this study it was attempted to find the position of the cannabinoid receptors in the large intestine and to determine their function. It was found that the cannabinoid receptors are distributed throughout the colon to find and that they play a role in alleviating IBD. Published in the journal "Gastroenterology."
3) Endocannabinoids and the gastrointestinal tract (gastrointestinal tract and the endocannabinoid - 2006)
This research was designed to explore the historical use of cannabis as a medicine in the treatment of gastrointestinal problems and whether cannabis really has an effect. It was found that the endocannabinoid system serves to protect the Verdauuungssystem against anomalies, which means that cannabis may be an effective way to treat those who suffer from such diseases. Published in the "U.S. National Library of Medicine."
4) Cannabis use in patients with chronic inflammatory bowel disease (Cannabis use amongst patients with inflammatory bowel disease - 2011)
Previous studies suggest that the endocannabinoid system plays a role in preventing and protecting against inflammation in the colon. Through questionnaires, which assessed the habits of cannabis use of patients with related disorders, it was found that the use of cannabis seemed to have a positive therapeutic benefit and further research should be carried out in this direction. Published in the "U.S. National Library of Medicine."
The "New York Times" is one of the most respected media outlets in the USA for the legalization of cannabis has spoken. In a sensational editorials have been for more than four decades valid prohibition with the times of Prohibition, from 1920 to 1933 is compared, were prohibited as manufacture and sale of alcohol in the United States strictly. It stated cannabis addiction bring compared to alcohol and tobacco dependence "relatively minor problems" with it.
In the editorial, the authors pointed out that pleasure-loving people would have been on drinking during Prohibition, which "law-abiding citizens have been turned into criminals and crime syndicates flourished." In addition, today were young black men, according to FBI statistics clearly bear the brunt of the result is "racist" cannabis prohibition.
According to the U.S. Federal Bureau of Investigation in 2012, there were over 650,000 arrests for possession of marijuana - much more than cocaine, heroin and related drugs. U.S. President Barack Obama had already indicated that poor youth who belong to social minorities, often for marijuana use in jail migrate as better-off peers.
Although the "New York Times" said in her - even for internal editorial controversial - contribution for a ban on the sale of marijuana to adolescents under 21 years. For healthy adults seem "moderate consumption" but to pose a risk, which is why the law adopted by Congress at the federal level more than four decades prohibition was untimely. On the website of the newspaper some readers warned against underestimating the danger of the popular "gateway drug", others called the legalization overdue.